1-6 of 6
Amanda L. Blackford
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges

Mohamad Dbouk, Toshiya Abe, Chiho Koi, Yohei Ando, Helena Saba, Elizabeth Abou Diwan, Anne MacGregor-Das, Amanda L. Blackford, Evelina Mocci, Katie Beierl, Ali Dbouk, Jin He, Richard Burkhart, Anne Marie Lennon, Lori Sokoll, Marcia Irene Canto, James R. Eshleman, Michael Goggins
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (20): 4178–4185.
https://doi.org/10.1158/1078-0432.CCR-23-0655
Published: 13 October 2023
View articletitled, Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges
Open the PDF for Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges in another window
Includes: Supplementary data
Journal Articles

The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial

Cesar A. Santa-Maria, Janelle W. Coughlin, Dipali Sharma, Mary Armanios, Amanda L. Blackford, Colleen Schreyer, Arlene Dalcin, Ashley Carpenter, Gerald J. Jerome, Deborah K. Armstrong, Madhu Chaudhry, Gary I. Cohen, Roisin M. Connolly, John Fetting, Robert S. Miller, Karen L. Smith, Claire Snyder, Andrew Wolfe, Antonio C. Wolff, Chiung-Yu Huang, Lawrence J. Appel, Vered Stearns
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12): 3024–3034.
https://doi.org/10.1158/1078-0432.CCR-19-2935
Published: 15 June 2020
View articletitled, The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial
Open the PDF for The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial in another window
Includes: Supplementary data
Journal Articles

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure

Amer M. Zeidan, Hanna A. Knaus, Tara M. Robinson, Andrea M.H. Towlerton, Edus H. Warren, Joshua F. Zeidner, Amanda L. Blackford, Amy S. Duffield, David Rizzieri, Mark G. Frattini, Yair M. Levy, Mark A. Schroeder, Anna Ferguson, Katherine E. Sheldon, Amy E. DeZern, Ivana Gojo, Steven D. Gore, Howard Streicher, Leo Luznik, B. Douglas Smith
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15): 3519–3527.
https://doi.org/10.1158/1078-0432.CCR-17-3763
Published: 31 July 2018
View articletitled, A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure
Open the PDF for A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma

Katherine E. Poruk, Amanda L. Blackford, Matthew J. Weiss, John L. Cameron, Jin He, Michael Goggins, Zeshaan A. Rasheed, Christopher L. Wolfgang, Laura D. Wood
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11): 2681–2690.
https://doi.org/10.1158/1078-0432.CCR-16-1467
Published: 31 May 2017
View articletitled, Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma
Open the PDF for Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia

Ivana Gojo, Jan H. Beumer, Keith W. Pratz, Michael A. McDevitt, Maria R. Baer, Amanda L. Blackford, B. Douglas Smith, Steven D. Gore, Hetty E. Carraway, Margaret M. Showel, Mark J. Levis, Amy E. Dezern, Douglas E. Gladstone, Jiuping Jay Ji, Lihua Wang, Robert J. Kinders, Marie Pouquet, Ismail Ali-Walbi, Michelle A. Rudek, Weijie Poh, James G. Herman, Larry M. Karnitz, Scott H. Kaufmann, Alice Chen, Judith E. Karp
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (3): 697–706.
https://doi.org/10.1158/1078-0432.CCR-16-0984
Published: 31 January 2017
View articletitled, A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
Open the PDF for A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity

Yunfeng Cui, Jacqueline A. Brosnan, Amanda L. Blackford, Surojit Sur, Ralph H. Hruban, Kenneth W. Kinzler, Bert Vogelstein, Anirban Maitra, Luis A. Diaz, Jr, Christine A. Iacobuzio-Donahue, James R. Eshleman
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (23): 6519–6530.
https://doi.org/10.1158/1078-0432.CCR-12-0827
Published: 29 November 2012
View articletitled, Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
Open the PDF for Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity in another window
Includes: Supplementary data